Skip to main content
eLife logoLink to eLife
. 2017 Aug 25;6:e29150. doi: 10.7554/eLife.29150

Autoinhibition of ankyrin-B/G membrane target bindings by intrinsically disordered segments from the tail regions

Keyu Chen 1,, Jianchao Li 1,, Chao Wang 1,2, Zhiyi Wei 1,3, Mingjie Zhang 1,4,
Editor: Axel T Brunger5
PMCID: PMC5779224  PMID: 28841137

Abstract

Ankyrins together with their spectrin partners are the master organizers of micron-scale membrane domains in diverse tissues. The 24 ankyrin (ANK) repeats of ankyrins bind to numerous membrane proteins, linking them to spectrin-based cytoskeletons at specific membrane microdomains. The accessibility of the target binding groove of ANK repeats must be regulated to achieve spatially defined functions of ankyrins/target complexes in different tissues, though little is known in this regard. Here we systemically investigated the autoinhibition mechanism of ankyrin-B/G by combined biochemical, biophysical and structural biology approaches. We discovered that the entire ANK repeats are inhibited by combinatorial and quasi-independent bindings of multiple disordered segments located in the ankyrin-B/G linkers and tails, suggesting a mechanistic basis for differential regulations of membrane target bindings by ankyrins. In addition to elucidating the autoinhibition mechanisms of ankyrins, our study may also shed light on regulations on target bindings by other long repeat-containing proteins.

Research organism: None

eLife digest

The membrane that surrounds the cells of animals is organized into regions known as microdomains. Different microdomains have different roles; for example, one microdomain may strengthen the cell while another may contain the apparatus used by cells to signal to each other.

A family of proteins called the ankyrins plays a central role in forming microdomains, and mutations to these proteins have been linked to many diseases, including heart rhythm abnormalities and bipolar disorder. Ankyrins connect certain proteins in the cell membrane to each other and to the network of microfilaments that organize the cell interior. A region called the membrane binding domain at one end of the ankyrin interacts with the membrane proteins. The other end, or “tail”, of the ankyrin is thought to regulate this interaction, although little is known about how it does so.

The members of the ankyrin family are similar but tend to localize to different parts of the cell and play different roles. Chen, Li et al. have now used biochemical and structural techniques to analyze the sequences of two ankyrins, called Ankyrin-B and Ankyrin-G. The results show that the tail regions of both of these proteins contain three “autoinhibition” segments that restrict the activity of the ankyrins. Each segment independently interacts with different sites on the ankyrin’s membrane binding domain, and this interaction joins the ends of the protein together into a ‘head-to-tail’ conformation that prevents it binding to membrane proteins. The autoinhibition segments of Ankyrin-B and Ankyrin-G are quite different, which Chen, Li et al. suggest could explain why these proteins have different activities.

Ankyrins play a vital role in many tissues, and so the findings presented by Chen, Li et al. will be of interest to scientists working in a wide range of basic biology and medical research fields. An immediate question for further investigation is how the autoinhibition of ankyrins is regulated to allow ankyrin-organized microdomains to form and work properly. Results from such studies will help researchers to understand the mechanisms that underlie diseases caused by mutations of ankyrins or the proteins that they bind to, and to develop potential therapies for these diseases.

Introduction

Ankyrins are a widely expressed scaffold protein family, which mainly function to link great varieties of functionally related but structurally diverse integral membrane proteins to the spectrin-based cytoskeletons (Bennett and Baines, 2001; Bennett and Healy, 2009; Bennett and Lorenzo, 2013). Mutations of ankyrins are known to be associated with various diseases in humans such as hereditary spherocytosis (Eber et al., 1996; Lux et al., 1990; Gallagher, 2005), cardiac arrhythmia syndromes and sinus node dysfunction (Mohler et al., 2003; Mohler et al., 2007; Le Scouarnec et al., 2008; Hashemi et al., 2009), bipolar disorders (Baum et al., 2008; Ferreira et al., 2008; Schulze et al., 2009; Scott et al., 2009; Takata et al., 2011; Dedman et al., 2012; Rueckert et al., 2013), schizophrenia (Nie et al., 2015; Ripke et al., 2011) and autism spectrum disorder (Willsey et al., 2013; Parikshak et al., 2013; Shi et al., 2013; Iqbal et al., 2013). In vertebrates, the ankyrin family consists of three members: ankyrin-R (AnkR), ankyrin-B (AnkB) and ankyrin-G (AnkG). They share similar domain organizations (Figure 1A), but usually locate at different subcellular regions and perform divergent physiological functions (Mohler et al., 2002; Abdi et al., 2006; He et al., 2013; Bennett and Lorenzo, 2016).

Figure 1. Biochemical and structural characterization of the AI-a/MBD interaction.

Figure 1.

(A) Schematic diagram showing the domain organizations of AnkR/B/G and their amino acid sequence identities. (B) Amino acid sequence alignments of AI-a from AnkB/G with several MBD ‘site-1’ binding sequences from AnkR CT or other targets. The critical Glu residues are highlighted with a green box. (C) Fluorescence polarization-based measurement of the binding affinity between AnkB_AI-a and AnkB_MBD or its R1 charge reversal mutant (‘EAAE’). (D) The design of AnkR/B_Chimera construct for crystallization. The AnkB_AI-a sequence (colored in salmon) was fused to the C-terminus of ‘site-2, 3’ binding AnkR_CT (colored in purple and magenta respectively). (E) ITC result showing the strong interaction between AnkR/B_Chimera and MBD. (F) Structural comparison of the MBD ‘site-1’ bindings of AnkB_AI-a (colored in green and salmon) and Nav_ABD (colored in cyan and purple) showing that the two bindings essentially share the same mode. Residues critical for the interaction were highlighted with stick models. Hydrogen bonds were indicated with dashed lines (the same labeling method is used throughout the manuscript for all structural figures).

Each ankyrin contains an N-terminal membrane binding domain (MBD), which is composed of 24 ANK repeats and responsible for binding to diverse membrane targets. The 24 ANK repeats of ankyrins are among the longest extended repeat-containing domains in living organisms. A trademark of long repeat-containing proteins is their formations of long solenoid structures with high conformational plasticity (Lee et al., 2006b; Wang et al., 2014). Following the MBD is an unstructured linker region of ~130 amino acid residues, followed sequentially by a ZU5-ZU5-UPA supramodule responsible for spectrin binding (SBD) (Mohler et al., 2004a; Wang et al., 2012), a death domain (DD), and an intrinsically disordered C-terminal tail (CT) with varying lengths (Figure 1A). The folded structural domains (i.e. MBD, SBD and DD) in ankyrins share very high sequence similarities (Figure 1A). In contrast, the unstructured regions of ankyrins (i.e. the linker region and CT), although fairly conserved within each isoform, are more divergent among the family members (Figure 1A). Presumably, these isoform-specific and unstructured linker and tail regions are largely responsible for distinct functions of each member of the ankyrin family proteins (see Abdi et al., 2006 and He et al., 2013 for examples). However, very little is known regarding how the unique linker and tail regions specifically modulate functions of each ankyrin.

Ankyrin is an ancient molecule that appeared as early as in bilaterians over 500 million years ago (Cai and Zhang, 2006; Bennett and Lorenzo, 2013). The 24 ANK repeats of ankyrins have retained a remarkable level of amino acid sequence conservation throughout the evolution, and different ANK repeats binding membrane proteins with diverse sequences have evolved at different stages of the evolution (Hill et al., 2008; Bennett and Lorenzo, 2013; Bennett and Lorenzo, 2016). In an earlier study, we demonstrated that the highly conserved 24 ANK repeats can form multiple semi-independent target binding sites, and each capable of recognizing short and intrinsically disordered segments with variable amino acid sequences distributed on target proteins (Wang et al., 2014). As such, ANK repeats are capable of binding to a very diverse array of target proteins with high specificity, a strategy that may be commonly employed by long repeat-containing scaffold proteins (Wang et al., 2014; Chook and Blobel, 2001; Conti et al., 1998; Graham et al., 2000; Huber and Weis, 2001; Kobe, 1999; Xu et al., 2010; Zhu et al., 2011). The target bindings of ankyrin’s ANK repeats must be regulated during the biogenesis and trafficking processes of ankyrins and their targets, as otherwise functionally unrelated membrane targets would be misdirected to the same sites in cellular membranes. Additionally, the formation of each ankyrin/target complex (e.g. the ankyrin-B/G and sodium channel complexes) at specific membrane domains also needs to be regulated to fulfill excitation/resting cycles of excitable tissues such as neurons and muscles (Bréchet et al., 2008; Garver et al., 1997; Whittard et al., 2006). Earlier studies have suggested that ankyrins can adopt autoinhibited conformation (i.e. by using sequences outside the ANK repeats to directly interact with the repeats) to regulate their target bindings (Abdi et al., 2006; Davis et al., 1992; He et al., 2013; Wang et al., 2014), but the mechanisms of the autoinhibition are unknown.

In this study, we systematically investigated the autoinhibition mechanisms of ANK repeats of ankyrin-B and G (AnkB and G). We identified three distinct autoinhibitory segments from the intrinsically disordered linker and CT regions of AnkB, and elucidated the inhibition mechanism of these segments by detailed biochemical and structural investigations. Our study reveals that the three inhibitory segments spread along the entire 24 ANK repeats and bind to the repeats in a quasi-independent manner, so that the inhibitory sites may be combinatorially regulated in response to different binding targets. We further demonstrated that AnkG also adopts a similar overall autoinhibition strategy as AnkB does, but with its own unique binding features. Collectively, the findings of our study not only provide a framework for understanding the interactions and regulations of ankyrins with their membrane targets, but may also be helpful in understanding the regulation of target recognitions by other long repeat-containing scaffold proteins in general.

Results

A segment in AnkB C-terminal tail binds to the N-terminal of ANK repeats

Ankyrin MBD can be inhibited by its CT regulatory domain in both AnkR and AnkB (Abdi et al., 2006; Davis et al., 1992), and previously we have biochemically and structurally characterized the intramolecular interaction between the 48-residue AnkR CT regulatory domain with all three MBDs from the ankyrin family members (Wang et al., 2014). Moreover, our analysis illustrated that the MBDs of AnkR/B/G are highly conserved and share essentially the same binding properties to diverse binding partners (Wang et al., 2014). In the structure of AnkB_MBD in complex with AnkR_CT, AnkR_CT adopts an extended conformation lining the inner groove of ANK repeats 1 ~ 14 of AnkB_MBD (Wang et al., 2014). Although AnkB and G do not contain AnkR_CT like sequences in their tails, more thorough sequence analysis revealed that both AnkB and G contain a 13-residue segment (denoted as ‘AI-a’ for the AutoInhibition segment-a, Figure 1A) that share a similar sequence pattern with the last 13-residue fragment of AnkR_CT and several MBD ‘site-1’ binding targets such as Na+ and K+-channels (Figure 1B). This 13-resdiue AI-a fragment is almost completely conserved in AnkB and AnkG among vertebrates (alignments not shown). Importantly, a Glu residue corresponding to Glu1622 in AnkR_CT and Glu1112 in Nav1.2, which has been shown to be absolutely required for AnkR_CT and Nav1.2 to bind to ANK repeats (Mohler et al., 2004b; Wang et al., 2014), is also invariant in AnkB and G (Figure 1B). We found that a peptide encompassing this AnkB_AI-a segment binds to AnkB ANK repeats with a dissociation constant (Kd) ~7.3 μM based on a fluorescence polarization binding assay (Figure 1C). Point mutations of the positively charged residues in the repeat 1 (R1) of ANK repeats (37RAAR40 to 37EAAE40) of AnkB significantly decreased its binding to the AI-a peptide (Figure 1C), consistent with our previous structural analysis that the positively charged residues in the ANK repeat R1 play a role in binding to the negatively charged residues from the ‘site-1’-binding peptides.

We attempted to elucidate the molecular basis governing the AnkB ANK repeats/AI-a interaction by solving the complex structure using a similar fusion strategy as we used earlier for the Nav1.2 peptide (Wang et al., 2014); i.e. by fusing ANK repeats R1-20 to the C-terminal tail of AnkB AI-a. However, this effort was not successful. As an alternative approach, we replaced the corresponding sequence of AnkR_CT with that of AnkB_AI-a and produced an AnkR/B_CT Chimera (Figure 1D). Isothermal titration calorimetry (ITC) experiments detected a strong interaction between this chimera peptide and AnkB_MBD, with a Kd value comparable to that of AnkR_CT with AnkB_MBD (Figure 1E). This chimera peptide was fused to the N-terminus of AnkB_MBD for crystallization trials as we have demonstrated for AnkR_CT. With this strategy, we successfully obtained crystals of the AnkR/B_CT Chimera/AnkB_repeats_R1-20 fusion protein, and the crystals were diffracted up to 3.3 Å. The structure of the fusion protein was determined by the molecular replacement method using the AnkB_repeats_R1-24 structure as the model (Wang et al., 2014) (Table 1). Consistent with the biochemical analysis, the structure showed that the AnkB_AI-a segment binds to ‘site-1’ of AnkB_MBD (repeats_R1-5) using essentially the same binding mode as we observed in the AnkR_CT/AnkB_MBD and Nav1.2_ABD/AnkB_R1-9 complex structures (Wang et al., 2014) (Figure 1F). In particular, Glu1630 from AnkB_AI-a occupies the identical position as Glu1622 in AnkR or Glu1112 in Nav1.2 on AnkB_R1-5, by forming strong hydrogen bonds with Thr94 and Asn98 in the R2-R3 finger loop (Figure 1F). Additionally, hydrophobic interactions between ‘PPIV’ from AI-a and hydrophobic residues (including the two critical Phe residues, Phe131 and Phe164, from R4 and R5; see Wang et al., 2014) from R3-R5 also contribute to the binding (Figure 1F).

Table 1. Statistics of X-ray Crystallographic Data Collection and Model refinement.

Data collection
 Data sets RB-Chimera/AnkB_R1-20 AI-b/AnkB_R8-M14 AI-c/AnkB_R13-24
 Space group R32 P6522 P212121
 Wavelength (Å) 0.979 0.979 0.979
 Unit Cell parameters (Å) a = b = 179.79, c = 227.10
α=β=90°, γ = 120°
a = b = 186.09, c = 75.35
α=β=90°, γ = 120°
a = 29.30, b = 127.80, c = 257.55
α=β=γ=90°
 Resolution range (Å) 50–3.3 (3.36–3.30) 50–2.35 (2.39–2.35) 50–1.95 (1.98–1.95)
 No. of unique reflections 20949 (1025) 31971 (1562) 68019 (3163)
 Redundancy 5.3 (5.5) 4.1 (3.8) 3.1 (3.2)
 I/σ 25.5 (3.3) 17.0 (2.0) 22.8 (2.4)
 Completeness (%) 97.6 (98.9) 97.5 (97.9) 94.4 (92.2)
 Rmerge* (%) 10.3 (72.1) 11.4 (89.3) 8.2 (70.3)
Structure refinement
 Resolution (Å) 50–3.3
(3.42–3.30)
50–2.35
(2.42–2.35)
50–1.95
(2.02–1.95)
 Rcryst/Rfree (%) 18.27/22.96
(25.40/31.06)
19.21/23.25 (24.28/28.57) 18.38/21.98 (24.40/29.34)
 Rmsd bonds (Å)/angles (°) 0.007/1.011 0.008/0.955 0.009/0.996
 Average B factor § 102.8 46.3 30.9
 No. of atoms
 Protein atoms 5019 3421 6128
 Water 0 64 274
 Other molecules 50 102 5
 No. of reflections
 Working set 18953 30384 64519
 Test set 1980 1540 3357
 Ramachandran plot regions §
 Favored (%) 95.2 98.0 98.7
 Allowed (%) 4.8 2.0 1.3
 Outliers (%) 0 0 0

Numbers in parentheses represent the value for the highest resolution shell.

* Rmerge = Σ |Ii - < I > | / ΣIi, where Ii is the intensity of measured reflection and <I > is the mean intensity of all symmetry-related reflections.

b† Rcryst=Σ||Fcalc| – |Fobs||/ΣFobs, where Fobs and Fcalc are observed and calculated structure factors.

c‡ Rfree= ΣT||Fcalc| – |Fobs||/ΣFobs, where T is a test data set of about 5% or 10% of the total unique reflections randomly chosen and set aside prior to refinement.

d§ B factors and Ramachandran plot statistics are calculated using MOLPROBITY (Chen et al., 2010).

Two discrete segments from the linker connecting AnkB MBD and SBD bind to the middle and C-terminal parts of ANK repeats respectively

Though the conservation among the three isoforms is limited, the amino acid sequences of the linker connecting MBD and SBD within each isoform of ankyrins are highly conserved (Figure 1A). The crystal structure of AnkR MBD C-terminal 12 ANK repeats (PDB ID: 1N11, referred to as AnkR_C12) contains a 14-residue fragment of the linker that folds back and binds to the last five repeats (R20-24) of MBD (Michaely et al., 2002) (also see below for more details). Recently, the linker region of AnkB was reported to directly interact with MBD, thus preventing AnkB from localizing to plasma membranes (He et al., 2013). These studies suggest that, besides the AI-a in their CT, the linker regions of ankyrins also play important autoinhibitory roles in regulating functions of MBDs.

We chose AnkB to investigate the detailed mechanism governing the linker region-mediated autoinhibition of ankyrins. To probe the linker-mediated autoinhibition, we used three AnkB_MBD binding targets (Nav1.2, E-cadherin and NF186/L1CAM), each with distinct MBD binding mode (see [Wang et al., 2014]; and our unpublished data on E-cadherin), to test their bindings to three versions of extended MBD: one containing a short 20-residue linker (aa 28–847, roughly corresponding to the above-mentioned AnkR_C12 structure but with additional six residues. See Table 2 for a list of key constructs used in the study), one containing the entire linker (aa 28–965), and the third one with the entire linker as well as the entire CT regulatory domain (i.e. the full-length AnkB with the spectrin binding ZZUD tandem deleted, denoted as AnkB ΔZZUD) (Figure 2A). Interestingly, extending the linker region from residue 847 to 965 (AnkB 28–847 vs AnkB 28–965) invariably led to weakened or completely loss of interactions between MBD and the three target proteins (Figure 2B and C), indicating that an additional segment within the residues 848–965 can bind to the ANK repeats of AnkB and acts as another autoinhibitory sequence. Including the AI-a fragment in the MBD extension (AnkB ΔZZUD) further eliminated the remaining binding of Nav1.2 (Figure 2B and C), and this is consistent with our findings that AI-a and Nav1.2 bind to R1-5 of MBD in a mutually competitive manner (Figure 1F; and Wang et al., 2014).

Table 2. Constructs of ankyrins used in this study.

AnkB AnkG
AI-a 1623–1635 1596–1608
AI-b 865–896 875–903
AI-c 828–852 837–858
Linker (contains AI-c + AI b) 828–965
AI-c + AI-b 828–896 837–920
Linker ΔAI-c 861–920
MBD + partial AI-c 28–847 38–855
MBD + full AI-c 28–873
MBD + AI c+AI-b 28–965 38–903
ΔZZUD
MBD 28–827 38–837

Figure 2. Two discrete segments in the AnkB linker region bind to MBD and inhibit its target binding.

Figure 2.

(A) Schematic diagram showing the three autoinhibitory segments (AI-a, b, c) located at the linker and CT regions of AnkB. (B) ITC derived binding affinities showing that including longer linker region or the AI-a segment to the AnkB MBD weakened its bindings to targets including Nav1.2, NF186/L1CAM, and E-cadherin. (C) Bar graph showing the levels of target binding decreases resulted by the autoinhibitory segments based on the binding data in Panel B. (D–F) ITC profiles showing direct interactions between the entire linker region of AnkB and different versions of AnkB MBD (D: 28–827, no linker, measured in buffer containing 500 mM NaCl due to poor quality of this protein in 100 mM NaCl buffer; E: 28–847, short linker roughly comparable to the AnkR_C12 structure; F: 28–873, longer linker containing the entire AI-c).

We confirmed the direct interaction between the entire linker (aa 828–965) with the AnkB ANK repeats only (aa 28–827) using an ITC-based binding assay, and data showed a strong binding (Kd about 0.044 μM, Figure 2D). The entire linker (aa 828–965) was found to bind to AnkB 28–847 with a Kd ~4.2 μM (Figure 2E), further indicating that a fragment within residues 848–965 can directly bind to AnkB_MBD. Another version of extended MBD, AnkB 28–873 interacts with the entire linker (aa 828–965) with a similar affinity as AnkB 28–847 does (Figure 2F), suggesting that residue 848–873 has marginal impact on the AnkB autoinhibition. Taken together, the above biochemical mapping experiments suggested that the AnkB linker region contains two discrete autoinhibitory segments: one segment within the region 848–965 binding to middle repeats of AnkB_MBD (denoted as AI-b), and the other within residues 828–847 overlapping with the short 14-residue segment observed in the AnkR_C12 structure (denoted as AI-c) (Figure 2A; and see below for further detailed mapping).

Structural basis of the AnkB AI-b/ANK repeats interaction

To delineate the mechanism governing the AI-b/MBD interaction, we set out to solve the complex structure. First, we mapped the minimal regions of AI-b and the corresponding repeats from MBD responsible for the interaction. Using the scheme described in Figure 2E as the assay, we mapped AI-b to a 32-aa fragment (aa 865–896) from the linker (Figure 3A). Using a similar approach combined with truncations of various repeats, we mapped the AI-b binding regions to R6-14 of MBD (Figure 3B).

Figure 3. Interaction between AnkB_AI-b and AnkB_MBD.

Figure 3.

(A) ITC-based mapping of the AnkB AI-b region. The minimal region of AI-b is indicated with a green box. The fragments with weakened or complete-loss of binding to MBD were shown in pink and grey bars, respectively. ‘ND’ represents no detectable binding in the ITC measurement and is used throughout the manuscript. (B) Similar mapping of the minimal ANK repeats responsible for AI-b binding. The repeats used for crystallization (R8-14) are highlighted with a black box. (C) The overall structure and an omit map showing the binding of AnkB_AI-b to AnkB_R8-14. The Fo-Fc density map was generated by deleting the AI-b part from the final model and contoured at 3.0 σ. The AI-b fitting the electron density is displayed in the stick model. (D) Detailed interactions between AnkB_AI-b and AnkB_MBD. The side chains or main chains of the residues involved in the interactions are highlighted in the stick model. Charge-charge and hydrogen bonding interactions are highlighted by dashed lines. (E) ITC derived dissociation constants showing mutations of critical residues weaken or abolish the binding. (F) Structural comparison showing the common hydrophobic pocket in MBD site-3 for binding of AnkB_AI-b and AnkR_CT. Met884 in AnkB_AI-b and Ile1588 in AnkR_CT as well as the residues forming the ‘site-3’ hydrophobic pocket are shown in stick model. Left: AnkB_AI-b/AnkB_MBD, middle: AnkR_CT/AnkB_MBD, right: superposition of these two.

We determined the crystal structure of AnkB repeats 8–14 fused to the C-terminus of AnkB_AI-b (aa 857–896) at 2.35 Å resolution (Table 1). The AI-b peptide binds to the inner groove formed by repeats 10–13 (Figure 3C), covering a large portion of the target binding ‘site-3’ (repeats 11–14) and a small portion of ‘site-2’ (repeats 7–10) that were defined in our previous study (Wang et al., 2014). The structure is also consistent with our biochemical data that the autoinhibitory interaction mediated by AI-b partially inhibits the binding of Nav1.2 and NF186 to MBD (Figure 2B), as both targets use the ‘site-3’ of MBD as one of the binding sites (Wang et al., 2014). Consistent with this observation, substitutions of hydrophobic residues within the ‘site-3’ with Gln (Leu366Gln, Phe399Gln, and Leu432Gln) completely disrupted AI-b’s binding to MBD, and substitutions of hydrophobic residues within the ‘site-2’ with Gln (Ile267Gln, Leu300Gln) mildly weakened the AI-b/MBD interaction (Figure 3E; see Wang et al., 2014 for the rational of the mutations).

The electron densities of the MBD_R8-14 bound AI-b only allowed us to trace residues spanning Gly883-Glu892 (Figure 3C). Although residues Glu865-Asp882 could not be traced in the crystal structure, this segment also directly participates in binding to MBD_R8-14, as deletion of residues from 865 to 873 significantly weakened AI-b’s binding to AnkB_MBD (Figure 3A). The structure of the MBD_R8-14/AI-b complex reveals their binding details: Tyr886 forms a hydrogen bond with His374 and hydrophobic interactions with Phe399 and Ile404; Met884 inserts into a hydrophobic pocket formed by Lys407, Val437, Phe440 and Met441; and Arg888 forms a number of hydrogen bonds with the sidechain of Tyr365 and backbone of Leu363 as well as charge-charge interaction with Asp364 (Figure 3D). ITC results showed that single point substitution of Tyr886 from AI-b with Ala significantly decreased its binding to MBD, and Met884Ala, Tyr886Ala double mutations totally abolished the AI-b’s autoinhibition (Figure 3E). It is noted that Met884 in AI-b occupies the same hydrophobic pocket as Ile1588 in AnkR_CT does, although the two ‘site-3’ binding fragments share very little amino acid sequence similarity (Figure 3F), further highlighting the remarkable capacity of ANK repeats in binding to targets with diverse amino acid sequences (Wang et al., 2014).

Biochemical and structural characterization of the AnkB AI-c/ANK repeats interaction

The AnkR_C12 structure contains a 14-residue linker region (aa 832–845 in mouse AnkR), and 11 residues (aa 835–845) are defined in the folded back structure (Michaely et al., 2002). A longer region of the linker (i.e. 828–849 in human AnkB) is highly conserved in all three isoforms of ankyrins (Figure 6A). We speculated that the autoinhibitory AI-c segment of ankyrins may be longer than the 11-residue fragment seen in the structure of AnkR_C12. To ensure that we do not miss any possible residues forming the AI-c binding segment, we prepared a C-terminal 12 ANK repeats of AnkB followed by a 46-residue linker (aa 430–873), which covers a small part of AI-b (Figure 3A), and solved the crystal structure of the protein at 1.95 Å resolution (Table 1). The overall structure of our AnkB C-terminal 12 repeats-linker is very similar to that of AnkR_C12 (RMSD of 1.04 Å, Figure 4A). However, our structure contains a longer linker folded back binding to the AnkB ANK repeats. A 20-residue linker (from Thr828 to Asp847 instead of 11 residues in AnkR_C12) is clearly defined, and this 20-residue linker extends to the repeat R18 (Figure 4A). Moreover, we observed a prominently positive-charged surface in the inner groove of R16-18 right next to Asp847, and the five residues following Asp847 are highly negatively charged and conserved (847DEEGDD852) (Figure 4B). We anticipate that this stretch of negatively charged residues is part of AI-c and involved in binding to MBD (likely R16-17 based on the length of the segment) (Figure 4B). This idea is supported by the data from an earlier study showing that substitution of ‘848EEGDDT853’ with ‘NAAIRS’ in AnkB led to increased membrane localization presumably due to the mutation-induced weakened autoinhibition (He et al., 2013). In the AI-c folded-back structure, residues from AI-c form extensive hydrogen bonds with the residues in finger loops of ANK repeats (Figure 4C). Perturbations of these hydrogen bonding interactions (e.g. the Asn834Lys substitution in AI-c or the Asn595Ala mutation in one of the ANK repeats finger loop) led to a few fold decreases in their bindings (Figure 4D). Hydrophobic interactions also contribute to the AI-c autoinhibition. Met839 is buried in the hydrophobic pocket formed by Leu668 and Leu701; Leu843 interacts with sidechains of Leu597, Tyr630, and Ile635 (Figure 4C). Individually mutating these two hydrophobic residues to polar Gln weakened the binding by several folds (Figure 4D).

Figure 4. Detailed interaction between AnkB_AI-c and AnkB_MBD.

Figure 4.

(A) Comparison of the structures of the AnkB_R13-24/AnkB_AI-c complex (colored in orange) and AnkR_C12 (colored in hot pink). The ANK repeats of AnkB are shown in cylinder and transparent surface and ANK repeats of AnkR are omitted for clarity. The folded back inhibitory sequence immediately following the ANK repeats in both structures are shown using the line model. The position of the stretch of negatively charged residues, which are not defined in the crystal structure, is indicated with a white oval. The amino acid sequence of AnkB_AI-c is also shown below the structure. Residues critical for the binding are shown in orange with those verified by mutagenesis highlighted by black triangles. (B) The charge potential surface of the inner groove formed by R16-17, calculated by the APBS module embedded in PyMOL and contoured at ±8 kT/e. (C) Detailed interactions between AnkB_AI-c and AnkB_MBD. (D) ITC derived dissociation constants showing mutations of critical residues weaken or abolish the binding between AnkB_AI-c and AnkB_MBD.

An ideal result would be to obtain structures of MBD of ankyrins binding to two or even all three of these autoinhibitory segments. We have extensively tried such experiments, by fusing the inhibitory fragments combining with the different strategies used in the study. Unfortunately, these extensive efforts have not resulted fruition likely due to the conformational dynamics of the elongated protein complexes.

The autoinhibition segments inhibit AnkB’s plasma membrane localization

In epithelial cells, AnkG clusters on plasma membranes whereas AnkB largely localizes to intracellular compartments (Figure 5A and B and He et al., 2013). Autoinhibition of the MBD by the linker region can modulate AnkB’s membrane vs cytosol distributions in epithelial cells (He et al., 2013). We made use of this assay as a functional readout to verify the autoinhibited structures determined in this study and to provide a preliminary glance at the role of AnkB’s autoinhibition. Consistent with the previous report (He et al., 2013), WT AnkB mainly localizes in the cytosol, whereas WT AnkG mainly associates with the plasma membranes in polarized MDCK cells (Figure 5A and B). We constructed two mutants in the linker region of AnkB, one weakens the AI-b’s binding to MBD (the Met884Ala, Tyr886Ala double point mutations, denoted as AnkB 2M) and the other weakens both AI-b and AI-c’s bindings to MBD (the Met884Ala, Tyr886Ala, Asn834Lys triple mutations, denoted as AnkB 3M), and assayed their membrane vs cytosol distributions in polarized MDCK cells. We observed that the AnkB 2M and 3M mutants show a higher ratio of plasma membrane localization (Figure 5A and B), consistent with releases of the autoinhibition induced by the two mutations. Finally, we deleted essentially the entire linker region encompassing the complete AI-b and AI-c segments (AnkB ΔLinker, with aa 828–943 deleted), and found that this deletion mutant is near completely membrane localized (Figure 5A and B), suggesting that both AI-b and AI-c can regulate AnkB’s membrane localization presumably by modulating its MBD’s binding to membrane-anchored target(s). We have also performed NF186-mediated plasma membrane recruitments of AnkB, and compared the impacts of the 2M and 3M mutations on AnkB’s membrane localizations in HeLa cells which lack endogenous NF186 expression. Co-expression of NF186 partially recruited WT AnkB to the plasma membranes (Figure 5C). The 2M, 3M, and ΔLinker of AnkB mutants displayed sequentially increasing amount of NF186-mediated membrane recruitments in this assay system (Figure 5C and D). Similar as observed in MDCK cells, WT AnkG is better recruited to plasma membranes by NF186 than WT AnkB is (Figure 5C and D).

Figure 5. The autoinhibitory segments regulate subcellular localization of AnkB in MDCK cells and NF186-dependent membrane recruitment of AnkB in HeLa cells.

Figure 5.

(A) Representative fluorescent images of transiently expressed GFP-tagged AnkG, AnkB or its linker mutants in polarized MDCK cells with nuclei stained with DAPI (blue): A1, WT AnkB; A2, WT AnkG; A3, AnkB_2M; A4, AnkB_3M; A5, AnkB ΔLinker. (B) Quantification of the immunofluorescence intensity ratio of plasma membrane vs cytosolic GFP signals. Data are presented as means ± SEM from>100 cells (except for AnkB ΔLinker with 41 cells due to its very clear membrane localizations) and analyzed using one way ANOVA followed by Dunnett’s multiple comparisons test to WT AnkB, ****p<0.0001. (C) Representative fluorescent images of HeLa cells transiently co-expressing HA-tagged NF186 (red) and GFP-tagged AnkG, AnkB or its linker mutants (green), with nuclei stained with DAPI (blue): C1, WT AnkB; C2, WT AnkG; C3, AnkB_2M; C4, AnkB_3M; C5, AnkB ΔLinker. (D) Quantification of the immunofluorescence intensity ratio of plasma membrane vs cytosolic GFP signals (representing AnkB/G level). Data are presented as means ± SEM from~20 cells and analyzed using one way ANOVA followed by Dunnett’s multiple comparisons test to WT AnkB, ****p<0.0001. The protein expression levels of all constructs in both cell lines are comparable as indicated by the quantified total fluorescence intensities of each groups in this experiment.

AnkG and AnkB share a similar autoinhibition mechanism

It is not known whether AnkG also contains auto-regulatory segments. Amino acid sequence alignment analysis reveals that residues corresponding to the AnkB AI-c are essentially the same in AnkG, indicating that AnkG also contains an autoinhibitory AI-c segment (Figure 6A). Curiously, the N-terminal half of AnkB AI-b can be nicely aligned with a fragment in the AnkG linker following AI-c, but residues in the C-terminal half of AnkB AI-b that are critical for its binding to MBD (e.g. Met884 and Tyr886) are missing in AnkG (Figure 6A). We hypothesized that AnkG may contain a different autoinhibitory AI-b segment from that of AnkB. Using a similar binding assay developed to discover AI-b in AnkB, we found that elongating the linker from residue 855 to 903 in the extended AnkG MBD (compare aa 38–855 vs aa 38–903) weakened the bindings of Nav1.2, E-cadherin and NF186 to AnkG by 6 ~ 74 folds (Figure 6B), indicating that AnkG linker indeed contains an AI-b segment. We also detected direct interaction between AnkG MBD-AI-c protein (aa 38–855, containing the AI-c segment) and an AnkG’s long linker (aa 837–920) or a shorter version of the linker (aa 861–920, lacking AI-c) (Figure 6C and D). Binding affinity-guided mapping revealed that residues 875 to 903 encompass the complete AI-b of AnkG (Figure 6E). It is noted that AnkG AI-b contains a stretch of highly charged residues in its N-terminal half, and these residues are not found in AnkB, revealing a different binding mechanism of AI-b to MBD in AnkB and G. We found that increasing salt concentrations in the binding buffer significantly weakened the interaction between AnkG_AI-b and AnkG_MBD, supporting the charge-charge interactions between AI-b and AnkG_MBD (data not shown). We substituted three charged residues with neutral or charge reverse residues (Asp887Ala, Asp889Ala and Lys890Glu, indicated with black triangles in Figure 6A) from the AnkG linker (861-920) and found that the mutant completely lost its ability to bind AnkG_MBD (Figure 6F), further supporting the critical roles of the charged residues in AnkG AI-b in its autoinhibition.

Figure 6. Autoinhibition of AnkG MBD by the linker region.

Figure 6.

(A) Amino acid sequence alignment of the linker regions of AnkG, AnkB, and AnkR. The boundaries of AI-c and AI-b of AnkB and G are indicated with orange and magenta boxes. Critical residues that have been verified by mutagenesis are highlighted with black triangles. (B) ITC-derived binding affinities showing that including longer linker region to the AnkG_MBD weakened the binding towards its binding targets Nav1.2, NF186/L1CAM, and E-cadherin. (C and D) ITC profiles showing direct binding of the linker of AnkG to AnkG_MBD: C, AnkG 837–920, a linker containing both AI-b and AI-c binding to AnkG_MBD; D, AnkG 861–920, a linker containing only the AI-b, binding to AnkG_MBD. (E) ITC-based mapping of the AnkG_AI-b region. The minimal region of AI-b is indicated with a green box. (F) ITC result showing that mutating the charged residues ‘DDK’ to Ala or charge reversed residue disrupted the binding between AnkG 861–920 to AnkG 38–855. (G) ITC-derived dissociation constants of AnkG 861–920 to AnkG WT and its ‘sites-1,2,3’ mutants showing that AnkG 861–920 predominantly binds to the ‘site-3’ of AnkG_MBD.

We attempted to map the AI-b’s binding site on AnkG’s ANK repeats by a similar repeats truncation approach used for AnkB (Figure 3B), but this effort failed due to poor sample behaviors of the AnkG_MBD truncation mutants. Alternatively, we generated the ‘site-1, -2, and -3’ target binding mutants of AnkG_MBD based on our earlier work (Wang et al., 2014), and tested each of these mutants in binding to the AnkG_AI-b fragment. We found that mutations in ”site-1’ (Phe141Gln, Phe164Gln) or in ‘site-2’ (Ile277Gln, Leu310Gln) of AnkG_MBD has little effect on AI-b’s binding, whereas mutations in ‘site-3’ (Leu376Gln, Phe409Gln, Leu442Gln) completely abolished the interaction between AI-b and ANK repeats (Figure 6G). This result indicates AnkG_AI-b also chiefly binds to the ‘site-3’ (repeats R11-14) of AnkG_MBD. The above result, together with the findings that AnkG also contains the inhibitory AI-a segment (Figure 1B) and AI-c segment (Figure 6A), collectively demonstrated that AnkG shares a very similar, three segment-mediated MBD autoinhibitory mechanism as AnkB does, although the AI-b segments in the two ankyrins are different.

Discussion

Features of the AnkB and G autoinhibition

Ankyrins are master scaffold proteins assembling very diverse signaling microdomains beneath membrane bilayers. This is achieved by their MBD-mediated bindings to numerous trans-membrane proteins and SBD-mediated anchoring of the protein complex to spectrin-based cytoskeletal meshwork. Formation of a highly elongated and malleable target binding groove by the 24 ANK repeats with multiple semi-independent target binding sites provides a mechanistic explanation to how ankyrin MBD, via combinatorial usages of its target binding sites, can bind to many distinct membrane targets with high specificity (Figure 7A; and Wang et al., 2014). A key unanswered question is how MBD-mediated recognitions of membrane targets of ankyrins are regulated. Autoinhibition by C-terminal segment(s) to the ANK repeats has been suggested to be one of such regulation mechanisms (Abdi et al., 2006).

Figure 7. Combinatorial autoinhibitions of ankyrins and their potential regulations.

Figure 7.

(A) Schematic diagram showing the combinatorial autoinhibition mechanisms of the three Ankyrin family members. ‘Sites-1,2,3’ are drawn according to our earlier study (Wang et al., 2014). R15-17 is assigned as ‘site-4’ based on the biochemical and structural analysis in this work and the concept that three to five ANK repeats can form a stable structural unit for target recognition, although no targets have been characterized to date. R18-24 is assigned as ‘site-5’ since it is autoinhibited by AI-c. The MBD binding sequences of the autoinhibitory segments or reported targets are shown in solid lines at corresponding positions of the bind sites. (B) Structural model of the autoinhibited full-length AnkB constructed with the three structures solved in the current study. The MBD is shown in surface representation. The three autoinhibitory segments are shown with the worm model. The unstructured loops are shown in grey dashed lines.

In this study, we characterized the autoinhibition of AnkB and G in detail and discovered that the entire target binding grooves of both AnkB and G MBDs could be inhibited by multiple discrete and intrinsically disordered peptide fragments located in the MBD/SBD linker region and in the tail region right after DD (Figure 7). Except for the AI-c segment located immediately C-terminal to the ANK repeats, the inhibitory sequences of AI-a and AI-b segments between AnkB and AnkG share limited homology. This is perhaps correlated with the differential potential target binding regulations of the two MBDs. However, the amino acid sequences of all three identified autoinhibitory segments are highly conserved throughout the evolution both for AnkB and for AnkG, implying that the autoinhibition mechanisms discovered here are evolutionary conserved features for the two ankyrins, respectively. Given that the inhibitory segments of both AnkB and G are intrinsically disordered and disordered sequences tend to evolve more rapidly in eukaryotic genomes (Dyson and Wright, 2005), such high amino acid sequence conservation suggests a strong function-mediated selection against mutational drifts of these inhibitory segments. Expressions of both AnkB and G can be extensively diverse due to their alternative splicing, and therefore the expressed proteins can vary in their sizes dramatically (Cunha and Mohler, 2009). However, regardless of the extensive alternative splicing, the autoinhibitory segments AI-b and AI-c are always retained in all documented AnkB or AnkG variants according to the Ensembl database (http://www.ensembl.org), suggesting that the autoinhibitory mechanisms characterized here for AI-b and c are common to all isoforms of AnkB and G. Interestingly, the giant AnkG isoforms (270 kDa/480 kDa AnkG) lose the AI-a segment due to alternative splicing; whereas giant AnkB (440 kDa AnkB) keeps this AI-a segment, suggesting the differential regulation of these giant ankyrin isoforms in nervous systems. Our data is also consistent with the findings from super-resolution images (Leterrier et al., 2015). In AIS, 270 kDa/480 kDa AnkG’s SBD exhibits a periodic pattern, while their C-terminus part is not periodically arranged and is found ~32 nm radially deeper than the SBD in the axoplasm. AIS AnkG (270 kDa/480 kDa isoforms) lacks AI-a, so the major parts of CT of 270 kDa/480 kDa AnkG are not sequestered by MBD even if AI-b and c are in contact with MBD. Furthermore, the 270 kDa/480 kDa AnkG at AIS/Nodes of Ranvier is likely to adopt an open conformation. As such, the signals of antibodies labeling the C-terminus part of AnkG should not appear near the membrane but is deeper into the axoplasm.

Since each target protein normally occupies a few of the total five proposed binding sites along the entire 24 ANK repeats (Figure 7A), the use of multiple semi-independent autoinhibitory segments lining the entire target binding groove of MBD can provide a mechanism for selected release of a few target binding sites (e.g. sites-1 and 3 for sodium channels) while keeping other sites closed (e.g. site-5), thus allowing selected engagements of MBD to certain target proteins at any given membrane microdomains. The combinatorial usage of multiple binding sites by target proteins appears to be a rather common strategy for many long repeat-containing proteins (Chook and Blobel, 2001; Conti et al., 1998; Graham et al., 2000; Huber and Weis, 2001; Kobe, 1999; Xu et al., 2010; Zhu et al., 2011). Autoinhibition of an elongated repeats domain by multiple intrinsically disordered segments from the same protein are rather uncommon, and only a few cases have been reported. Kap60p, a karyopherin family protein, adopts a somewhat similar autoinhibition mode as ankyrins do. In this case, two NLS recognition sites on the armadillo repeats were shown to be autoinhibited by two consecutive segments from Kap60p’s N-terminal unstructured region (Matsuura and Stewart, 2004). In another case, two NLS binding sites of importin-α are inhibited by the same fragment from its N-terminal unstructured region at a 1:2 stoichiometry instead of multiple segments with different sequences as found in ankyrins and Kap60p (Catimel et al., 2001). Other autoinhibition mechanisms found in long repeat-containing proteins include the HEAT repeats of karyopherin-β2 occupied by an internal long loop from the middle region of the HEAT repeats (Chook and Blobel, 1999; Lee et al., 2006a), the HEAT repeats of exportin chromosome region maintenance 1 (CRM1) autoinhibited by a C-terminal α helix immediately following the HEAT repeats (Saito and Matsuura, 2013), and the armadillo repeats of Diaphanous-related formins (Drfs) autoinhibited by a short α helix from its distal C-terminal region (Lammers et al., 2005). It will be interesting to investigate whether the autoinhibition by multiple discrete segments as observed in ankyrins here might also be used by other long repeat-containing proteins capable of binding to diverse targets in the future.

Functional implications and potential regulations of ankyrin autoinhibition

Ankyrin MBDs are versatile membrane target binders and many of these ankyrin binding membrane proteins are located in specific membrane microdomains (e.g. ion-channels in the axon initial segments of neurons as well as specifically patterned membrane domains in cardiomyocytes) playing vital physiological roles. Defects of interactions between ankyrins and their membrane targets are frequently linked to human diseases including hereditary spherocytosis, cardiac arrhythmia, and several types of psychiatric disorders (Eber et al., 1996; Mohler et al., 2004b; Van Camp et al., 1996). In view of the vital physiological roles of the interactions between ankyrins and these membrane targets, a priori assumption is that such ankyrin-mediated membrane target bindings must be regulated. For example, the membrane target binding groove of MBDs is likely to be closed, via the autoinhibition mechanism elucidated in this study, during biogenesis and trafficking processes of ankyrins. Upon reaching each specific membrane domain, certain mechanisms are likely existing to release a few selected target binding sites for specific assembly of ankyrin/membrane target complexes. The existence of multiple semi-independent inhibitory sequences in the tail of ankyrins suggests that these sequence may be regulated in a combinatorial fashion so that ankyrins can scaffold many different target proteins in different cellular settings and in different tissues.

The positioning of the spectrin binding ZZUD domains with respect to the auto-inhibitory sites-a and b suggests a possible spectrin/SBD interaction-induced release of ankyrin autoinhibition. The spectrin binding ZZUD tandem are flanked by the AI-a and AI-b segments both in 220 kDa AnkB and 190 kDa AnkG, and the connection sequences between the ZZUD tandem and the two inhibitory segments are not very long (Figures 1A and 7B). Once ankyrins and spectrins meet at specific membrane microdomains, both the bulky ankyrin SBD/spectrin complex as well as the perceived ‘pulling force’ exerted by the spectrin-bound SBD may dislodge the two inhibitory segments, AI-a and AI-b, flanking the ZZUD tandem and thus lead to the release of the autoinhibition. Accompanied by the spectrin binding-induced release of the AI-a and AI-b segments, the target binding ‘sites-1,2,3’ are opened and the corresponding membrane proteins can bind to the ankyrin MBDs. It should be noted that such coordinated membrane microdomain targeting and spectrin/actin network binding-induced release of ankyrin MBD autoinhibition model, if it is indeed employed in cells, is likely used together with other regulatory mechanisms in regulating the conformational opening of ankyrins. Ankyrins at AIS/nodes of Ranvier are chiefly 270 kDa/480 kDa AnkG isoforms. Interestingly, these two larger AnkG isoforms do not contain the ‘AI-a’ sequence in their CTs due to alternative splicing. Thus, the 270 kDa/480 kDa AnkG seem to have different autoinhibition mechanisms with respect to other ankyrins (e.g. 190 kDa AnkG and 220 kDa AnkB). The lack of the ‘AI-a’ site in 270 kDa/480 kDa AnkG means that these two AnkG isoforms can still bind to Nav channels or NF186 (See Figure 2B, AnkB 28–965; and also Hedstrom et al., 2008), albeit with much lower affinities (i.e. a form of semi-open conformation). Spectrin binding to the AnkG SBD may promote further opening of ANK repeats and thus leading to full engagements of the membrane targets of AnkG. Such mutual reinforcement of AnkG-mediated membrane microdomain assembly model is consistent with the findings showing that membrane targets and βIV spectrin mutually stabilize each other through AnkG at AIS or nodes of Ranvier (Yang et al., 2004; Patzke et al., 2016). Additionally, post-translational modifications (e.g. phosphorylation by different protein kinases) can provide another level of differential activations of ankyrins (see below).

Although AnkB and AnkG share the similar overall autoinhibition modes, the detailed amino acid sequences in their autoinhibitory segments are quite different (Figures 6A and 7A). In parallel with this finding, AnkB and AnkG are often targeted to different subdomains in the same tissues including neurons and cardiomyocytes (Galiano et al., 2012; Lowe et al., 2008; Mohler et al., 2005). It is possible that the unique sequences of their inhibitory segments provide means for AnkB and G to be differentially regulated. One such possible mean is via post translational modifications such as phosphorylations (Lu et al., 1985; Cianci et al., 1988). We surveyed the PhosphoSitePlus database (http://www.phosphosite.org/) and found that Ser855 in AI-c, Thr888, Tyr891 in AI-b of AnkG and Thr838, Ser846 in AI-c, Tyr889, Ser890 in AI-b of AnkB can be phosphorylated. These residues are positioned within the autoinhibitory segments. It is possible that phosphorylation on some of these residues may lead to differential releases of the MBD autoinhibition of AnkB or AnkG. Again, the disordered nature of the autoinhibitory segments of ankyrins is favorable for their accesses to different protein kinases. It is further noted that different ankyrin-enriched membrane microdomains (for example AIS) are often selectively enriched with certain protein kinases (Bréchet et al., 2008; Hund et al., 2010; Tapia et al., 2013). Post translational modifications on the intrinsically disordered inhibitory segments of ankyrins as a mean of their target recognition regulations may be a fertile ground to explore in the future.

In summary, we systemically studied the autoinhibition mechanisms of the 24 ANK repeats of AnkB and G by their own respective MBD/SBD linker and proximal tail segments. We biochemically characterized these intramolecular interactions, solved the representative complex structures and quantitatively evaluated the inhibitory effects of these autoinhibitory segments on MBD’s bindings to different physiological membrane targets. We demonstrated that the combinatorial uses of multiple semi-independent, intrinsically disordered autoinhibitory segments can provide graded regulations of targets binding by ankyrin MBDs. Our findings on the autoinhibition as well as target bindings of the 24 ANK repeats of ankyrins may also shed light on target recognitions and regulations by other long repeat-containing scaffold proteins that are quite abundant in the mammalian proteomes.

Materials and methods

Constructs, protein expression and purification

The coding sequences of the AnkR constructs were PCR amplified from a mouse muscle cDNA library. The coding sequences of AnkB and AnkG constructs were PCR amplified from the full-length human 220 kDa AnkB template or the full-length rat 270 kDa AnkG template respectively (both templates as well as the HA tagged full length NF186 construct are generous gifts from Dr. Vann Bennett). E-cadherin (aa 734–884), NF186 (aa 1187–1214), L1CAM (aa 1206–1233) and Nav1.2 (aa 1035–1129) coding sequences were PCR amplified from mouse brain or muscle cDNA libraries. All of the constructs that used for protein expression were cloned onto a home-modified pET32a vector. All truncation mutations of ANK repeats constructs were made with the same strategy as described in our previous study (Wang et al., 2014). The fusion constructs of AnkR/B_CT Chimera/AnkB_repeats_R1-20 and AnkB_AI-b/AnkB_R8-M14 were made by standard two-step PCR with a coding sequence of ‘GSLVPRGSGS’ as the flexible linker (M14 means replacing the αB of R14 with a capping sequence corresponding to the αB of R24 for protein stabilization as we used earlier). The same strategy was used in making other fusion constructs described in this study. All point mutations were created using the Quick Change site-directed mutagenesis kit and confirmed by DNA sequencing. Protein expression and purification protocols are the same as previously described (Wang et al., 2012; 2014). Recombinant proteins were expressed in BL21 (DE3) Escherichia coli cells with induction of 0.25 mM IPTG at 16°C. The N-terminal Trx-his6-tagged proteins were purified using Ni2+-NTA agarose affinity column followed by size-exclusion chromatography (Superdex 200 column from GE Healthcare, Little Chalfont, UK) in the final buffer containing 50 mM Tris-HCl, 1 mM DTT, and 1 mM EDTA, pH 7.8 with either 100 mM NaCl or 500 mM NaCl as required.

For simplicity, we use human 220 kDa AnkB (NM_020977.3), rat AnkG (MBD-UPA: NM_001033984.1 and DD-CT: NM_031805.1) and mouse AnkR (NM_001110783.3) for the amino acid numbering throughout the manuscript. The various constructs of ankyrins used in this study are listed in Table 2.

Isothermal titration calorimetry assay and fluorescence assay

Isothermal titration calorimetry (ITC) assays and fluorescence assays were carried out with the same protocol as described earlier (Wang et al., 2014). Briefly, isothermal titration calorimetry assays were performed on a VP-ITC MicroCal calorimeter (MicroCal, Northampton, MA) at 25°C and data were analyzed and fitted using the program Origin7.0 (Microcal). Fluorescence-based binding assays were performed on a PerkinElmer LS-55 fluorimeter equipped with an automated polarizer at 25°C. The Kd values were obtained by fitting the titration curves with the classical one-site binding model.

Crystallography

All crystals were obtained by hanging drop or sitting drop vapor diffusion methods at 16°C. Crystals of AnkR/B_CT Chimera/AnkB_repeats_R1-20 were grown in solution containing 4 M ammonium acetate and 0.1 M Bis-Tris propane (pH 7.0). Crystals of AnkB_AI-b/AnkB_R8-M14 were grown in solution containing 0.1 M HEPES (pH 7.0), 1 M ammonium sulfate and 0.5% w/v PEG 8,000. Crystals of AnkB_AI-c/AnkB_R13-24 were grown in solution containing 0.2 M CaCl2, 0.1 M HEPES (pH 7.5) and 28% v/v PEG 400. Crystals were soaked in crystallization solution containing additional 20% glycerol for cryoprotection. All datasets were collected at the Shanghai Synchrotron Radiation Facility at 100 K. Data were processed and scaled using HKL2000 (Otwinowski and Minor, 1997).

Structures were solved by molecular replacement using PHASER (McCoy et al., 2007) with fragments of the entire 24 ANK repeats (PDB: 4RLV) as the searching models. Peptides were manually built according to Fo-Fc difference maps in COOT (Emsley et al., 2010). Further manual model adjustment and refinement were completed iteratively using COOT (Emsley et al., 2010) and PHENIX (Adams et al., 2010). The final models were validated by MolProbity (Chen et al., 2010) and statistics are summarized in Table 1. All structure figures were prepared by PyMOL (http://www.pymol.org). The coordinates of the structures reported in this work have been deposited to PDB under the accession codes of 5Y4D, 5Y4E and 5Y4F for the RB-Chimera/AnkB_R1-20, AI-b/AnkB_R8-M14 and AI-c/AnkB_R13-24 structures, respectively.

Cell culture, transfection and immunostaining

MDCK cells were seeded on 35 mm dishes with 10 mm diameter uncoated glass bottom (MatTek, Ashland, MA) and grown in 10% FBS supplemented DMEM at 37°C incubator with 5% CO2. After around 20 hr, when the confluency reached 30 ~ 40%, cells were transfected with 300 ng plasmids using Lipofectamine 2000 transfection reagent (Invitrogen, Carsbad, CA) following the protocol suggested by the manufacturer. After transfection, MDCK cells were grown in 10% FBS supplemented DMEM until they were fully polarized. HeLa cells were cultured in the same media and culture condition as used for MDCK cells. HeLa cells were co-transfected with 400 ng HA tagged NF186 plasmids and 500 ng ankyrin constructs using Viafect transfection reagent (Promega, Madison, WI) when the confluency reached 20 ~ 30%. Then cells were grown in 10% FBS supplemented DMEM for 24 hr and fixed. HeLa (RRID: CVCL_0030) and MDCK (RRID: CVCL_0422) cells were originated from ATCC. These cells were not individually authenticated and not found to be on the list of commonly misidentified cell lines (International Cell Line Authentication Committee). Cells were tested negative for mycoplasma contamination by cytoplasmic DAPI staining.

The MDCK or HeLa cells were fixed with 4% paraformaldehyde at room temperature for 15 min, and permeabilized with 0.2% Triton X-100 at room temperature for 15 min followed by a 60 min blocking in PBS buffer containing 5% bovine serum albumin. For immunostaining, cells were then incubated with primary antibodies (goat anti GFP, ab6658, Lot: GR206330-6, RRID: AB_305631; Rabbit anti HA, Sigma, H6908, RRID: AB_260070) at 4°C overnight. The next day, cells were washed with PBS buffer three times and then incubated with fluorescence-conjugated secondary antibodies (Alexa Fluor 488 or 594) at room temperature for 2 hr, followed by incubating with 500 nM DAPI for 5 min to stain nucleus. Then cells were washed with PBS before imaging.

Microscopy and data analysis

All the cell culture images were captured by a Zeiss LSM 880 laser-scanning confocal microscope. The MDCK cell and HeLa cell images were captured using a 40 × 1.4 oil objective with pinhole setting to 1 Airy unit. Fluorescence intensity were analyzed with ImageJ software (https://imagej.nih.gov/ij/) and statistically analyzed with GraphPad Prism five using one-way ANOVA followed by Dunnett’s multiple comparisons test.

Acknowledgements

We thank the Shanghai Synchrotron Radiation Facility (SSRF) BL19U1 and BL17U1 for X-ray beam time. We also thank Dr. Vann Bennett for valuable discussions and experimental materials from his laboratory at Duke University. This work was supported by grants from RGC of Hong Kong (663812, 664113, 16103614, and AoE-M09-12), and a 973 program grant (2014CB910204) and a National Key R and D Program (2016YFA0501900) from the Minister of Science and Technology of China to MZ. MZ is a Kerry Holdings Professor in Science and a Senior Fellow of IAS at HKUST.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Mingjie Zhang, Email: mzhang@ust.hk.

Axel T Brunger, Stanford University Medical Center, United States.

Funding Information

This paper was supported by the following grants:

  • Research Grants Council, University Grants Committee 663812 to Mingjie Zhang.

  • Ministry of Science and Technology of the People's Republic of China 2014CB910204 to Mingjie Zhang.

  • Research Grants Council, University Grants Committee 664113 to Mingjie Zhang.

  • Research Grants Council, University Grants Committee 16103614 to Mingjie Zhang.

  • Research Grants Council, University Grants Committee AoE-M09-12 to Mingjie Zhang.

  • Ministry of Science and Technology of the People's Republic of China 2016YFA0501903 to Mingjie Zhang.

Additional information

Competing interests

Reviewing editor, eLife.

No competing interests declared.

Author contributions

Data curation, Formal analysis, Investigation, Writing—original draft, Writing—review and editing.

Data curation, Formal analysis, Investigation, Writing—original draft, Writing—review and editing.

Data curation, Formal analysis, Investigation, Writing—review and editing.

Data curation, Formal analysis, Investigation, Writing—review and editing.

Conceptualization, Supervision, Writing—original draft, Writing—review and editing.

Additional files

Transparent reporting form
DOI: 10.7554/eLife.29150.012

References

  1. Abdi KM, Mohler PJ, Davis JQ, Bennett V. Isoform specificity of ankyrin-B: a site in the divergent C-terminal domain is required for intramolecular association. The Journal of Biological Chemistry. 2006;281:5741–5749. doi: 10.1074/jbc.M506697200. [DOI] [PubMed] [Google Scholar]
  2. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D Biological Crystallography. 2010;66:213–221. doi: 10.1107/S0907444909052925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Molecular Psychiatry. 2008;13:197–207. doi: 10.1038/sj.mp.4002012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett V, Baines AJ. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. Physiological reviews. 2001;81:1353–1392. doi: 10.1152/physrev.2001.81.3.1353. [DOI] [PubMed] [Google Scholar]
  5. Bennett V, Healy J. Membrane domains based on ankyrin and spectrin associated with cell-cell interactions. Cold Spring Harbor Perspectives in Biology. 2009;1:a003012. doi: 10.1101/cshperspect.a003012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bennett V, Lorenzo DN. Spectrin- and Ankyrin-Based Membrane Domains and the Evolution of Vertebrates. In: Bennet V, editor. Current Topics in Membranes. Academic Press; 2013. pp. 1–37. [DOI] [PubMed] [Google Scholar]
  7. Bennett V, Lorenzo DN. Chapter Five - An Adaptable Spectrin/Ankyrin-Based Mechanism for Long-Range Organization of Plasma Membranes in Vertebrate Tissues. In: Bennett V, editor. Current Topics in Membranes. Academic Press; 2016. pp. 143–184. [DOI] [PubMed] [Google Scholar]
  8. Bréchet A, Fache M-P, Brachet A, Ferracci G, Baude A, Irondelle M, Pereira S, Leterrier C, Dargent B. Protein kinase CK2 contributes to the organization of sodium channels in axonal membranes by regulating their interactions with ankyrin G. The Journal of Cell Biology. 2008;183:1101–1114. doi: 10.1083/jcb.200805169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cai X, Zhang Y. Molecular evolution of the ankyrin gene family. Molecular Biology and Evolution. 2006;23:550–558. doi: 10.1093/molbev/msj056. [DOI] [PubMed] [Google Scholar]
  10. Catimel B, Teh T, Fontes MR, Jennings IG, Jans DA, Howlett GJ, Nice EC, Kobe B. Biophysical characterization of interactions involving importin-alpha during nuclear import. Journal of Biological Chemistry. 2001;276:34189–34198. doi: 10.1074/jbc.M103531200. [DOI] [PubMed] [Google Scholar]
  11. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallographica Section D Biological Crystallography. 2010;66:12–21. doi: 10.1107/S0907444909042073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chook YM, Blobel G. Structure of the nuclear transport complex karyopherin-beta2-Ran x GppNHp. Nature. 1999;399:230–237. doi: 10.1038/20375. [DOI] [PubMed] [Google Scholar]
  13. Chook YM, Blobel G. Karyopherins and nuclear import. Current Opinion in Structural Biology. 2001;11:703–715. doi: 10.1016/S0959-440X(01)00264-0. [DOI] [PubMed] [Google Scholar]
  14. Cianci CD, Giorgi M, Morrow JS. Phosphorylation of ankyrin down-regulates its cooperative interaction with spectrin and protein 3. Journal of Cellular Biochemistry. 1988;37:301–315. doi: 10.1002/jcb.240370305. [DOI] [PubMed] [Google Scholar]
  15. Conti E, Uy M, Leighton L, Blobel G, Kuriyan J. Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha. Cell. 1998;94:193–204. doi: 10.1016/S0092-8674(00)81419-1. [DOI] [PubMed] [Google Scholar]
  16. Cunha SR, Mohler PJ. Ankyrin protein networks in membrane formation and stabilization. Journal of Cellular and Molecular Medicine. 2009;13:4364–4376. doi: 10.1111/j.1582-4934.2009.00943.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Davis LH, Davis JQ, Bennett V. Ankyrin regulation: an alternatively spliced segment of the regulatory domain functions as an intramolecular modulator. The Journal of biological chemistry. 1992;267:18966–18972. [PubMed] [Google Scholar]
  18. Dedman A, McQuillin A, Kandaswamy R, Sharp S, Anjorin A, Gurling H. Sequencing of the ANKYRIN 3 gene (ANK3) encoding ankyrin G in bipolar disorder reveals a non-conservative amino acid change in a short isoform of ankyrin G. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2012;159B:328–335. doi: 10.1002/ajmg.b.32030. [DOI] [PubMed] [Google Scholar]
  19. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nature Reviews Molecular Cell Biology. 2005;6:197–208. doi: 10.1038/nrm1589. [DOI] [PubMed] [Google Scholar]
  20. Eber SW, Gonzalez JM, Lux ML, Scarpa AL, Tse WT, Dornwell M, Herbers J, Kugler W, Ozcan R, Pekrun A, Gallagher PG, Schröter W, Forget BG, Lux SE. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nature Genetics. 1996;13:214–218. doi: 10.1038/ng0696-214. [DOI] [PubMed] [Google Scholar]
  21. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallographica Section D Biological Crystallography. 2010;66:486–501. doi: 10.1107/S0907444910007493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S, Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M, Morris DW, Elkin A, Muir WJ, McGhee KA, Williamson R, MacIntyre DJ, MacLean AW, St CD, Robinson M, Van Beck M, Pereira AC, Kandaswamy R, McQuillin A, Collier DA, Bass NJ, Young AH, Lawrence J, Ferrier IN, Anjorin A, Farmer A, Curtis D, Scolnick EM, McGuffin P, Daly MJ, Corvin AP, Holmans PA, Blackwood DH, Gurling HM, Owen MJ, Purcell SM, Sklar P, Craddock N, Wellcome Trust Case Control Consortium Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nature Genetics. 2008;40:1056–1058. doi: 10.1038/ng.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Galiano MR, Jha S, Ho TS, Zhang C, Ogawa Y, Chang KJ, Stankewich MC, Mohler PJ, Rasband MN. A distal axonal cytoskeleton forms an intra-axonal boundary that controls axon initial segment assembly. Cell. 2012;149:1125–1139. doi: 10.1016/j.cell.2012.03.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Gallagher PG. Hematologically important mutations: ankyrin variants in hereditary spherocytosis. Blood Cells, Molecules, and Diseases. 2005;35:345–347. doi: 10.1016/j.bcmd.2005.08.008. [DOI] [PubMed] [Google Scholar]
  25. Garver TD, Ren Q, Tuvia S, Bennett V. Tyrosine phosphorylation at a site highly conserved in the L1 family of cell adhesion molecules abolishes ankyrin binding and increases lateral mobility of neurofascin. The Journal of Cell Biology. 1997;137:703–714. doi: 10.1083/jcb.137.3.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Graham TA, Weaver C, Mao F, Kimelman D, Xu W. Crystal structure of a beta-catenin/Tcf complex. Cell. 2000;103:885–896. doi: 10.1016/S0092-8674(00)00192-6. [DOI] [PubMed] [Google Scholar]
  27. Hashemi SM, Hund TJ, Mohler PJ. Cardiac ankyrins in health and disease. Journal of Molecular and Cellular Cardiology. 2009;47:203–209. doi: 10.1016/j.yjmcc.2009.04.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. He M, Tseng WC, Bennett V. A single divergent exon inhibits ankyrin-B association with the plasma membrane. Journal of Biological Chemistry. 2013;288:14769–14779. doi: 10.1074/jbc.M113.465328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hedstrom KL, Ogawa Y, Rasband MN. AnkyrinG is required for maintenance of the axon initial segment and neuronal polarity. The Journal of Cell Biology. 2008;183:635–640. doi: 10.1083/jcb.200806112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hill AS, Nishino A, Nakajo K, Zhang G, Fineman JR, Selzer ME, Okamura Y, Cooper EC. Ion channel clustering at the axon initial segment and node of Ranvier evolved sequentially in early chordates. PLoS Genetics. 2008;4:e1000317. doi: 10.1371/journal.pgen.1000317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell. 2001;105:391–402. doi: 10.1016/S0092-8674(01)00330-0. [DOI] [PubMed] [Google Scholar]
  32. Hund TJ, Koval OM, Li J, Wright PJ, Qian L, Snyder JS, Gudmundsson H, Kline CF, Davidson NP, Cardona N, Rasband MN, Anderson ME, Mohler PJ. A β(IV)-spectrin/CaMKII signaling complex is essential for membrane excitability in mice. Journal of Clinical Investigation. 2010;120:3508–3519. doi: 10.1172/JCI43621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Iqbal Z, Vandeweyer G, van der Voet M, Waryah AM, Zahoor MY, Besseling JA, Roca LT, Vulto-van Silfhout AT, Nijhof B, Kramer JM, Van der Aa N, Ansar M, Peeters H, Helsmoortel C, Gilissen C, Vissers LE, Veltman JA, de Brouwer AP, Frank Kooy R, Riazuddin S, Schenck A, van Bokhoven H, Rooms L. Homozygous and heterozygous disruptions of ANK3: at the crossroads of neurodevelopmental and psychiatric disorders. Human Molecular Genetics. 2013;22:1960–1970. doi: 10.1093/hmg/ddt043. [DOI] [PubMed] [Google Scholar]
  34. Kobe B. Autoinhibition by an internal nuclear localization signal revealed by the crystal structure of mammalian importin alpha. Nature Structural Biology. 1999;6:388–397. doi: 10.1038/7625. [DOI] [PubMed] [Google Scholar]
  35. Lammers M, Rose R, Scrima A, Wittinghofer A. The regulation of mDia1 by autoinhibition and its release by Rho*GTP. The EMBO Journal. 2005;24:4176–4187. doi: 10.1038/sj.emboj.7600879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Le Scouarnec S, Bhasin N, Vieyres C, Hund TJ, Cunha SR, Koval O, Marionneau C, Chen B, Wu Y, Demolombe S, Song LS, Le Marec H, Probst V, Schott JJ, Anderson ME, Mohler PJ. Dysfunction in ankyrin-B-dependent ion channel and transporter targeting causes human sinus node disease. PNAS. 2008;105:15617–15622. doi: 10.1073/pnas.0805500105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lee BJ, Cansizoglu AE, Süel KE, Louis TH, Zhang Z, Chook YM. Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell. 2006a;126:543–558. doi: 10.1016/j.cell.2006.05.049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Lee G, Abdi K, Jiang Y, Michaely P, Bennett V, Marszalek PE. Nanospring behaviour of ankyrin repeats. Nature. 2006b;440:246–249. doi: 10.1038/nature04437. [DOI] [PubMed] [Google Scholar]
  39. Leterrier C, Potier J, Caillol G, Debarnot C, Rueda Boroni F, Dargent B. Nanoscale Architecture of the Axon Initial Segment Reveals an Organized and Robust Scaffold. Cell Reports. 2015;13:2781–2793. doi: 10.1016/j.celrep.2015.11.051. [DOI] [PubMed] [Google Scholar]
  40. Lowe JS, Palygin O, Bhasin N, Hund TJ, Boyden PA, Shibata E, Anderson ME, Mohler PJ. Voltage-gated Nav channel targeting in the heart requires an ankyrin-G dependent cellular pathway. The Journal of Cell Biology. 2008;180:173–186. doi: 10.1083/jcb.200710107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lu PW, Soong CJ, Tao M. Phosphorylation of ankyrin decreases its affinity for spectrin tetramer. The Journal of biological chemistry. 1985;260:14958–14964. [PubMed] [Google Scholar]
  42. Lux SE, Tse WT, Menninger JC, John KM, Harris P, Shalev O, Chilcote RR, Marchesi SL, Watkins PC, Bennett V. Hereditary spherocytosis associated with deletion of human erythrocyte ankyrin gene on chromosome 8. Nature. 1990;345:736–739. doi: 10.1038/345736a0. [DOI] [PubMed] [Google Scholar]
  43. Matsuura Y, Stewart M. Structural basis for the assembly of a nuclear export complex. Nature. 2004;432:872–877. doi: 10.1038/nature03144. [DOI] [PubMed] [Google Scholar]
  44. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. Journal of Applied Crystallography. 2007;40:658–674. doi: 10.1107/S0021889807021206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Michaely P, Tomchick DR, Machius M, Anderson RG. Crystal structure of a 12 ANK repeat stack from human ankyrinR. The EMBO Journal. 2002;21:6387–6396. doi: 10.1093/emboj/cdf651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Mohler PJ, Gramolini AO, Bennett V. The ankyrin-B C-terminal domain determines activity of ankyrin-B/G chimeras in rescue of abnormal inositol 1,4,5-trisphosphate and ryanodine receptor distribution in ankyrin-B (-/-) neonatal cardiomyocytes. Journal of Biological Chemistry. 2002;277:10599–10607. doi: 10.1074/jbc.M110958200. [DOI] [PubMed] [Google Scholar]
  47. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogné K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421:634–639. doi: 10.1038/nature01335. [DOI] [PubMed] [Google Scholar]
  48. Mohler PJ, Yoon W, Bennett V. Ankyrin-B targets beta2-spectrin to an intracellular compartment in neonatal cardiomyocytes. Journal of Biological Chemistry. 2004a;279:40185–40193. doi: 10.1074/jbc.M406018200. [DOI] [PubMed] [Google Scholar]
  49. Mohler PJ, Rivolta I, Napolitano C, LeMaillet G, Lambert S, Priori SG, Bennett V. Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes. PNAS. 2004b;101:17533–17538. doi: 10.1073/pnas.0403711101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Mohler PJ, Davis JQ, Bennett V. Ankyrin-B coordinates the Na/K ATPase, Na/Ca exchanger, and InsP3 receptor in a cardiac T-tubule/SR microdomain. PLoS Biology. 2005;3:e423. doi: 10.1371/journal.pbio.0030423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Driskell IM, Schott JJ, Norris K, Leenhardt A, Kim RB, Escande D, Roden DM. Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation. 2007;115:432–441. doi: 10.1161/CIRCULATIONAHA.106.656512. [DOI] [PubMed] [Google Scholar]
  52. Nie F, Wang X, Zhao P, Yang H, Zhu W, Zhao Y, Chen B, Valenzuela RK, Zhang R, Gallitano AL, Ma J. Genetic analysis of SNPs in CACNA1C and ANK3 gene with schizophrenia: A comprehensive meta-analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2015;168:637–648. doi: 10.1002/ajmg.b.32348. [DOI] [PubMed] [Google Scholar]
  53. Otwinowski Z, Minor W. [20] Processing of X-ray diffraction data collected in oscillation mode. Methods in enzymology. 1997;276:307–326. doi: 10.1016/S0076-6879(97)76066-X. [DOI] [PubMed] [Google Scholar]
  54. Parikshak NN, Luo R, Zhang A, Won H, Lowe JK, Chandran V, Horvath S, Geschwind DH. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell. 2013;155:1008–1021. doi: 10.1016/j.cell.2013.10.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Patzke C, Acuna C, Giam LR, Wernig M, Südhof TC. Conditional deletion of L1CAM in human neurons impairs both axonal and dendritic arborization and action potential generation. The Journal of Experimental Medicine. 2016;213:499–515. doi: 10.1084/jem.20150951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin D-Y, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St. Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DHR, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jönsson EG, Bitter I, Pietiläinen OPH, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang K-Y, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Ørntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CCA, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV, Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium Genome-wide association study identifies five new schizophrenia loci. Nature Genetics. 2011;43:969–976. doi: 10.1038/ng.940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Rueckert EH, Barker D, Ruderfer D, Bergen SE, O'Dushlaine C, Luce CJ, Sheridan SD, Theriault KM, Chambert K, Moran J, Purcell SM, Madison JM, Haggarty SJ, Sklar P. Cis-acting regulation of brain-specific ANK3 gene expression by a genetic variant associated with bipolar disorder. Molecular Psychiatry. 2013;18:922–929. doi: 10.1038/mp.2012.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Saito N, Matsuura Y. A 2.1-Å-resolution crystal structure of unliganded CRM1 reveals the mechanism of autoinhibition. Journal of Molecular Biology. 2013;425:350–364. doi: 10.1016/j.jmb.2012.11.014. [DOI] [PubMed] [Google Scholar]
  59. Schulze TG, Detera-Wadleigh SD, Akula N, Gupta A, Kassem L, Steele J, Pearl J, Strohmaier J, Breuer R, Schwarz M, Propping P, Nöthen MM, Cichon S, Schumacher J, Rietschel M, McMahon FJ, NIMH Genetics Initiative Bipolar Disorder Consortium Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Molecular Psychiatry. 2009;14:487–491. doi: 10.1038/mp.2008.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, Tozzi F, Li JZ, Burmeister M, Absher D, Thompson RC, Francks C, Meng F, Antoniades A, Southwick AM, Schatzberg AF, Bunney WE, Barchas JD, Jones EG, Day R, Matthews K, McGuffin P, Strauss JS, Kennedy JL, Middleton L, Roses AD, Watson SJ, Vincent JB, Myers RM, Farmer AE, Akil H, Burns DK, Boehnke M. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. PNAS. 2009;106:7501–7506. doi: 10.1073/pnas.0813386106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Shi L, Zhang X, Golhar R, Otieno FG, He M, Hou C, Kim C, Keating B, Lyon GJ, Wang K, Hakonarson H. Whole-genome sequencing in an autism multiplex family. Molecular Autism. 2013;4:8. doi: 10.1186/2040-2392-4-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Takata A, Kim SH, Ozaki N, Iwata N, Kunugi H, Inada T, Ujike H, Nakamura K, Mori N, Ahn YM, Joo EJ, Song JY, Kanba S, Yoshikawa T, Kim YS, Kato T. Association of ANK3 with bipolar disorder confirmed in East Asia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2011;156B:312–315. doi: 10.1002/ajmg.b.31164. [DOI] [PubMed] [Google Scholar]
  63. Tapia M, Del Puerto A, Puime A, Sánchez-Ponce D, Fronzaroli-Molinieres L, Pallas-Bazarra N, Carlier E, Giraud P, Debanne D, Wandosell F, Garrido JJ. GSK3 and β-catenin determines functional expression of sodium channels at the axon initial segment. Cellular and Molecular Life Sciences. 2013;70:105–120. doi: 10.1007/s00018-012-1059-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Van Camp G, Fransen E, Vits L, Raes G, Willems PJ. A locus-specific mutation database for the neural cell adhesion molecule L1CAM (Xq28) Human Mutation. 1996;8:391. doi: 10.1002/(SICI)1098-1004(1996)8:4&#x0003c;391::AID-HUMU19&#x0003e;3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  65. Wang C, Yu C, Ye F, Wei Z, Zhang M. Structure of the ZU5-ZU5-UPA-DD tandem of ankyrin-B reveals interaction surfaces necessary for ankyrin function. PNAS. 2012;109:4822–4827. doi: 10.1073/pnas.1200613109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Wang C, Wei Z, Chen K, Ye F, Yu C, Bennett V, Zhang M. Structural basis of diverse membrane target recognitions by ankyrins. eLife. 2014;3:e04353. doi: 10.7554/eLife.04353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Whittard JD, Sakurai T, Cassella MR, Gazdoiu M, Felsenfeld DP. MAP kinase pathway-dependent phosphorylation of the L1-CAM ankyrin binding site regulates neuronal growth. Molecular Biology of the Cell. 2006;17:2696–2706. doi: 10.1091/mbc.E06-01-0090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, Reilly SK, Lin L, Fertuzinhos S, Miller JA, Murtha MT, Bichsel C, Niu W, Cotney J, Ercan-Sencicek AG, Gockley J, Gupta AR, Han W, He X, Hoffman EJ, Klei L, Lei J, Liu W, Liu L, Lu C, Xu X, Zhu Y, Mane SM, Lein ES, Wei L, Noonan JP, Roeder K, Devlin B, Sestan N, State MW. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell. 2013;155:997–1007. doi: 10.1016/j.cell.2013.10.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin-β proteins. Current Opinion in Structural Biology. 2010;20:782–790. doi: 10.1016/j.sbi.2010.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Yang Y, Lacas-Gervais S, Morest DK, Solimena M, Rasband MN. BetaIV spectrins are essential for membrane stability and the molecular organization of nodes of Ranvier. Journal of Neuroscience. 2004;24:7230–7240. doi: 10.1523/JNEUROSCI.2125-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Zhu J, Wen W, Zheng Z, Shang Y, Wei Z, Xiao Z, Pan Z, Du Q, Wang W, Zhang M. LGN/mInsc and LGN/NuMA complex structures suggest distinct functions in asymmetric cell division for the Par3/mInsc/LGN and Gαi/LGN/NuMA pathways. Molecular Cell. 2011;43:418–431. doi: 10.1016/j.molcel.2011.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision letter

Editor: Axel T Brunger1

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "Autoinhibition of ankyrin-B/G membrane target bindings by intrinsically disordered segments from the tail regions" for consideration by eLife. Your article has been reviewed favorably by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and John Kuriyan as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Yuh Min Chook (Reviewer #1); Peter Michaely (Reviewer #2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Note that the essential revisions listed below do not require additional experiments, but please discuss your response to each of the points thoroughly, and revise the manuscript accordingly.

Summary:

The manuscript from the Zhang group revealed how ankyrin proteins are autoinhibited by three disordered segments – two from the linker region and one from the C-terminal disordered region of the proteins. They used a combination of quantitative mapping by ITC and X-ray crystallography to identify these three segments in all three ankyrin isoforms AnkB, AnkG and AnkR. The finding is important as this work provides the first mechanistic explanation of how binding of the ankyrins to different membrane targets that occupy different sites on the ankyrin MBD may be regulated differentially as the three autoinhibitory segments each occupy different sites along the ankyrin repeat solenoid.

Essential revisions:

1) This point concerns limitations of the model proposed by the authors. The authors propose a mechanism whereby binding of ankyrins to spectrins releases the AI domains allowing them to interact with their membrane binding targets. This model is not consistent with the fact that AnkG recruits bIV spectrin to the AIS, and that NF186 recruits ankG to nodes of Ranvier. Clustered ankG recruits spectrins to the AIS and nodes (see Yang et al., JCB), and clustering of ankG at the AIS does not require βIV spectrin (see Hedstrom et al., JCB) to cluster Na+ channels or NF186. While the model is plausible, the authors should discuss the limitations of the model. Moreover, the authors hypothesize that association of ankyrin with spectrin activates MBD associations with client membrane proteins. This hypothesis is attractive, but on its surface, seems to be in conflict with published data showing that full-length ankyrins purified from tissue can associate with high affinity to at least many of ankyrins' membrane protein clients in the absence of spectrin (e.g., PMID: 2452986, 3039371, 379653). The authors also hypothesize that phosphorylation events in the CTD may activate specific client associations by displacing CTD sequences blocking aspects of the MBD. This too is an attractive hypothesis and is one that has previously been suggested (e.g., PMID 2933395, 2970468). It may be that ankyrins are synthesized in a "closed" conformation, and upon interaction with spectrin, adopt a semi-open conformation that makes C-terminal sequences targets for phosphorylation. These phosphorylation events may then activate membrane protein binding activity. Ankyrins purified from tissues may have existent CTD phosphorylations that allow interaction with membrane proteins. As also discussed by the authors, the CTD is subject to extensive alternative splicing resulting in different ankyrins with different regulatory sequences. mRNA splicing events that eliminate specific blocking sequences may promote select membrane proteins interactions. The presence of specific CTD sequences have also been shown to promote specific associations (PMID: 16368689). The characterization of how individual ankyrins preferentially associate with specific subsets of client membrane proteins is beyond the scope of this work; however, the limitations of the proposed models should be discussed, especially in the context of the above-mentioned publications.

2) The description of mapping of AI-c for AnkB (exothermic to endothermic binding and biphasic binding in Figure 4—figure supplement 1) is difficult to follow and as described not very useful.

3) It would be useful if the authors could comment on autoinhibitory mechanisms in other repeat protein systems, and how they compare to the process they have uncovered in the ankyrins.

4) The authors should comment on how their results fit with the STORM imaging of ankG at axon initial segments together using antibodies directed against different domains of ankG. Leterrier et al., Cell Reports 2015.

5) Is it possible that the three AI domain interactions are cooperative? In other words, does affinity increase with two AI domains or three AI domains together?

6) Subsection “Features of the AnkB&G autoinhibition”, end of second paragraph. What evidence is there that alternative splicing doesn't affect the autoinhibitory mechanisms? Perhaps not the binding, but certainly the availability of the AI domains.

eLife. 2017 Aug 25;6:e29150. doi: 10.7554/eLife.29150.014

Author response


Essential revisions:

1) This point concerns limitations of the model proposed by the authors. The authors propose a mechanism whereby binding of ankyrins to spectrins releases the AI domains allowing them to interact with their membrane binding targets. This model is not consistent with the fact that AnkG recruits bIV spectrin to the AIS, and that NF186 recruits ankG to nodes of Ranvier. Clustered ankG recruits spectrins to the AIS and nodes (see Yang et al., JCB), and clustering of ankG at the AIS does not require βIV spectrin (see Hedstrom et al., JCB) to cluster Na+ channels or NF186. While the model is plausible, the authors should discuss the limitations of the model. Moreover, the authors hypothesize that association of ankyrin with spectrin activates MBD associations with client membrane proteins. This hypothesis is attractive, but on its surface, seems to be in conflict with published data showing that full-length ankyrins purified from tissue can associate with high affinity to at least many of ankyrins' membrane protein clients in the absence of spectrin (e.g., PMID: 2452986, 3039371, 379653). The authors also hypothesize that phosphorylation events in the CTD may activate specific client associations by displacing CTD sequences blocking aspects of the MBD. This too is an attractive hypothesis and is one that has previously been suggested (e.g., PMID 2933395, 2970468). It may be that ankyrins are synthesized in a "closed" conformation, and upon interaction with spectrin, adopt a semi-open conformation that makes C-terminal sequences targets for phosphorylation. These phosphorylation events may then activate membrane protein binding activity. Ankyrins purified from tissues may have existent CTD phosphorylations that allow interaction with membrane proteins. As also discussed by the authors, the CTD is subject to extensive alternative splicing resulting in different ankyrins with different regulatory sequences. mRNA splicing events that eliminate specific blocking sequences may promote select membrane proteins interactions. The presence of specific CTD sequences have also been shown to promote specific associations (PMID: 16368689). The characterization of how individual ankyrins preferentially associate with specific subsets of client membrane proteins is beyond the scope of this work; however, the limitations of the proposed models should be discussed, especially in the context of the above-mentioned publications.

We thank the reviewers/editors for the wonderful comments and suggestions above. We fully agree with the reviewers/editors that our proposed model is not adequate and in several cases does not fit well with the literature observations of AnkG targeting and AnkG-mediated βIV spectrin and membrane protein recruitments at AIS/nodes of Ranvier. The likely scenario is that many regulatory mechanisms are used in a combinatorial fashion so that ankyrins can scaffold various target proteins in different cellular settings and in different tissues. The fully inhibited state of ankyrins with all three inhibitory segments (AI-a,b,c) occupying the ANK repeats may be an extreme state when ankyrins are synthesized and being trafficked to different cellular locations. Our proposed spectrin binding-induced ANK repeats opening, even if it is indeed employed in cells, is one of many regulatory mechanisms in activating ankyrins. We have revised our model and expanded the discussion about the model to include this critical point.

Alternative splicing is another way in regulating functions of ankyrins. Ankyrins at AIS/nodes of Ranvier are chiefly 270 kDa/480 kDa AnkG isoforms. Interestingly, these two larger AnkG isoforms do not contain the “AI-a” sequence in their CTDs due to alternative splicing. Thus, the 270 kDa/480 kDa AnkG seem to have different autoinhibition mechanisms with respect to other ankyrins (e.g. 190 kDa AnkG and 220 kDa AnkB). The lack of the “AI-a” site in 270 kDa/480kDa AnkG means that these two AnkG isoforms can still bind to Nav channels or NF186 (See Figure 2B, AnkB 28-965; and also Hedstrom et al. JCB, 2008), albeit with much lower affinities (i.e. a form of semi-open conformation). Spectrin binding to the AnkG SBD may promote further opening of ANK repeats and thus leading to full engagements of the membrane targets of AnkG. Such mutual reinforcement of AnkG-mediated membrane microdomain assembly model is consistent with the findings showing that membrane targets and βIV spectrin mutually stabilize each other through AnkG at AIS or nodes of Ranvier (Yang et al., J neurosci 2004; Patzke et al., J Exp Med, 2016). Additionally, post-translational modifications (e.g. phosphorylation by different protein kinases) can provide another level of differential activations of ankyrins.

We have significantly revised the model and descriptions of the model to reflect the above points.

2) The description of mapping of AI-c for AnkB (exothermic to endothermic binding and biphasic binding in Figure 4—figure supplement 1) is difficult to follow and as described not very useful.

Thanks for the suggestion. We have removed the “Figure 4—figure supplement 1” and changed the corresponding descriptions in the revised manuscript.

3) It would be useful if the authors could comment on autoinhibitory mechanisms in other repeat protein systems, and how they compare to the process they have uncovered in the ankyrins.

We agree with the reviewers/editors’ suggestion and have modified the Discussion section to compare autoinhibition mechanisms of some other repeat-containing proteins. The combinatorial usage of multiple binding sites to engage their binding partners also exists in other elongated repeats containing proteins (Chook and Blobel, 2001; Conti et al., 1998; Graham et al., 2000; Huber and Weis, 2001; Kobe, 1999; Xu et al., 2010; Zhu et al., 2011). Whereas autoinhibition of an elongated repeats domain by multiple intrinsically discorded segments from the same protein seems to be much less common. A somewhat similar autoinhibition as ankyrins do is a karyopherin family protein importin-α. In that case, two NLS recognition sites on the armadillo repeats were shown to be autoinhibited by a sequence from importin-α’s N-terminal unstructured region (Catimel et al., 2001). It is noted that, unlike ankyrins, these two binding sites are inhibited by the exact same segment in a 1:2 stoichiometry instead of multiple segments with different sequences found in ankyrins. Except for ankyrin, only limited structures of autoinhibited repeats domains have been reported (PDB ID: 4KXF, 2BAP, 3VYC, 1IQ1 and 1IAL). Two of them are importin-α as mentioned above (1IQ1 and 1IAL); one is the armadillo repeats of Diaphanous-related formins (Drfs) autoinhibited by a short α helix from its distal C-terminal region (2BAP); one is the HEAT repeats of exportin chromosome region maintenance 1 (CRM1) autoinhibited by an immediate C-terminal α helix following the HEAT repeats (3VYC); and one is the nucleotide-binding and oligomerization domain-like receptor protein (NLRC4). The leucine-rich repeats (LRR) of NLRC4 is positioned to sterically occlude one side of NLRC4’s NBD domain and consequently sequester NLRC4 in a monomeric state. We have discussed these in the revised manuscript.

4) The authors should comment on how their results fit with the STORM imaging of ankG at axon initial segments together using antibodies directed against different domains of ankG. Leterrier et al., Cell Reports 2015.

Our data is consistent with the findings by Leterrier et al. They demonstrated that AnkG’s SBD exhibits a periodic pattern, while the C-terminus part of AnkG is not periodically arranged and is found ~32 nm radially deeper than the SBD in the axoplasm. AIS AnkG (270 kDa/480 kDa isoforms) does not contain AI-a on its CTs due to alternative splicing, so the major parts of CT of 270 kDa/480 kDa AnkG are not sequestered by MBD even if AI-b&c are in contact with MBD. As we have touched in our response to the comment #1, the conformation of 270 kDa/480 kDa AnkG at AIS/Nodes of Ranvier is likely open. As such, the signals of antibodies labeling the C-terminus part of AnkG should not appear near the membrane but is deeper into the axoplasm. Additionally, as the giant insertion regions and CTs of 270 kDa/480 kDa AnkG are largely unstructured, this probably explains why the CT is not periodically arranged in the STORM imaging experiments.

5) Is it possible that the three AI domain interactions are cooperative? In other words, does affinity increase with two AI domains or three AI domains together?

The AI domains in ankyrins are only partially cooperative. For example, the Kd of AI-b/MBD interaction is ~3.7 μM (Figure 3B) and the Kd of AI-c/MBD interaction is ~0.36 μM (Figure 4D); a linker sequence (AnkB 828-965) that contains both AI-b and AI-c binding to MBD with a Kd roughly 0.044 μM (Figure 2D); If AI-b and AI-c are fully cooperative, the apparent Kd should be ~1 pM (3.7 μM × 0.36 μM ≈ 1.3 pM) instead of observed ~0.044 μM. The synergism between AI-a and AI-b is expected to be much weaker than that of AI-b and AI-c, because the spacing sequence between AI-a and AI-b segments is much longer than that of AI-b and AI-c (Figure 7). Such weak cooperativity among the inhibitory sites is advantageous for the combinatorial regulation model of ankyrins as we have described in our response to the comment #1. Though thermodynamically plausible, but proving such model by experiments is not an easy task.

6) Subsection “Features of the AnkB&G autoinhibition”, end of second paragraph. What evidence is there that alternative splicing doesn't affect the autoinhibitory mechanisms? Perhaps not the binding, but certainly the availability of the AI domains.

We searched the Ensembl (http://www.ensembl.org) database and found that in all the available splicing variant sequences of AnkB or AnkG (except for variants that without ANK repeats), both AI-b and AI-c are preserved in all variants. So, it seems that the sequences of AI-b and AI-c are not affected by alternative splicing in all AnkB/G variants. However, it is noted that the giant ankyrin-G isoforms (i.e. the 270 kDa/480 kDa AnkG) contain AI-b and AI-c in their linker regions but lose AI-a in their CTs due to alternative splicing. In contrast, the giant Ankyrin-B (i.e. 440 kDa AnkB) contains all three AI segments. Additionally, for AnkR, AI-a is missing in some splicing variants. We have revised the second paragraph of the subsection “Features of the AnkB&G autoinhibition” to make a clear description.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Transparent reporting form
    DOI: 10.7554/eLife.29150.012

    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES